Other Events ·
FDA grants Breakthrough Therapy Designation to Praxis's elsunersen for SCN2A-related seizures
PRAXPraxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. announced on June 22, 2026, that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for elsunersen (PRAX-222), an antisense oligonucleotide intended to treat seizures associated with SCN2A Developmental and Epileptic Encephalopathy (DEE). The designation is supported by preliminary clinical evidence from the EMBRAVE Part A trial, a Phase 1/2 study in pediatric patients. Praxis Precision Medicines, Inc. is a biopharmaceutical company focused on the development of medicines for neurological disorders.